Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Genus delivers 'strong' underlying group trading performance in FY25

(Sharecast News) - Animal genetics firm Genus said on Tuesday that it had delivered a "strong" underlying group trading performance in the year ended 30 June, in line with expectations. Genus said it had delivered "double-digit underlying growth" adjusted operating profits in its PIC unit, with an additional net £3.7m milestone receipt following US Food and Drug Administration approval of its PRP gene edit.

The FTSE 250-listed firm also said its ABS wing had performed ahead of expectations in H2, with value acceleration programme initiatives continuing to be "the primary driver" of adjusted operating profit growth.

"As a result of good trading and the PRP milestone receipt, the board now expects group FY25 adjusted profit before tax to be at least £72.0m in actual currency. Excluding the net £3.7m PRP milestone receipt, FY25 adjusted PBT is expected to be at least £68.0m in actual currency, in line with expectations," said Genus.

Genus added that H2 group cash conversion continued to be "very strong", resulting in strong growth in free cash flow and a reduction in leverage to less than 1.6x at year-end.

As of 0820 BST, Genus shares were up 1.79% at 2,275.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.